Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • EULAR 2026

European Alliance of Associations for Rheumatology (EULAR) - 2026

June 03 - 06, 2026

  1. All
  2. SAPHNELO (anifrolumab)
  3. Immunology Unbranded
  4. FASENRA (benralizumab)

PDF

Treatment with anifrolumab prevents organ damage accrual compared with real-world standard of care in patients with systemic lupus erythematosus: analysis of the LASER study over 4 years

PDF

Anifrolumab treatment is associated with DORIS remission in adults with systemic lupus erythematosus: real-world outcomes from an academic lupus registry

PDF

Efficacy of subcutaneous anifrolumab across multiple organ systems in patients with moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-SC trial

PDF

Achievement and maintenance of glucocorticoid reduction without increasing flare risk in Asian patients with SLE treated with anifrolumab: post-hoc analysis of the AZALEA trial

HTML

DORIS Remission and LLDAS Attainment After up to 12 Months of Real-world Anifrolumab Treatment: Interim Results From the ASTER Study

HTML

Improved SLE Disease Activity Across Multiple Organ Systems After up to 12 Months of Real-World Treatment With Anifrolumab: Interim Results From the ASTER Study

HTML

Anifrolumab treatment in patients with Sjögren's disease: Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase-IIa proof-of-mechanism trial (ANISE-II)

PDF

DORIS remission and LLDAS attainment in patients with systemic lupus erythematosus treated with subcutaneous anifrolumab with and without on-study immunosuppressant use: post hoc analysis of the TULIP-SC trial

HTML

The Impact of Subcutaneous Anifrolumab on Patient-Reported Outcomes in Patients With SLE: Results From the Phase 3 TULIP-SC Trial

HTML

Interferon Receptor Blockade With Anifrolumab Mitigates Plasma-Induced Glomerular Inflammation in a 3D Human Glomerular Spheroid Model

HTML

Anifrolumab in patients with systemic lupus erythematosus: real-world data from the Spanish BIOBADASER 3.0 registry

HTML

Real-World Trends in Renal, Hematologic, and Immunologic Parameters With Anifrolumab in Patients Diagnosed With Systemic Lupus Erythematosus Using Administrative Claims Linked to Laboratory Data

HTML

Remission achievement in SLE: real-world evidence from the AZAHAR study in spain

HTML

Single-cell analysis of interferon blockade uncovers B cell repertoire remodeling in systemic lupus erythematosus

HTML

A new endpoint for SLE clinical trials: the Treatment Response Measure for Systemic Lupus Erythematosus clinical trials (TRM-SLE)

PDF

Variation in demographics and clinical features among adults with moderate-to-severe systemic lupus erythematosus by US insurance type

HTML

Association of the treatment response measure for SLE (TRM-SLE) renal response thresholds with long-term outcomes in patients with lupus nephritis

HTML

First phases of the clinical validation of an online-tool estimating one year risk of activity event in Systemic Lupus Erythematosus: the AGILES solution

HTML

Longitudinal serum proteomic signatures associated with durable remission versus relapse after CAR-T therapy in autoimmune diseases

HTML

Phenotypic changes of the peripheral B cell compartment precede the first case of relapsed SLE after CD19 CAR-T cell therapy

PDF

Association between daily dose of oral glucocorticoids and infections in patients with eosinophilic granulomatosis with polyangiitis treated with anti-interleukin-5/receptor therapies

PDF

Treatment with anifrolumab prevents organ damage accrual compared with real-world standard of care in patients with systemic lupus erythematosus: analysis of the LASER study over 4 years

PDF

Anifrolumab treatment is associated with DORIS remission in adults with systemic lupus erythematosus: real-world outcomes from an academic lupus registry

PDF

Efficacy of subcutaneous anifrolumab across multiple organ systems in patients with moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-SC trial

PDF

Achievement and maintenance of glucocorticoid reduction without increasing flare risk in Asian patients with SLE treated with anifrolumab: post-hoc analysis of the AZALEA trial

HTML

DORIS Remission and LLDAS Attainment After up to 12 Months of Real-world Anifrolumab Treatment: Interim Results From the ASTER Study

HTML

Improved SLE Disease Activity Across Multiple Organ Systems After up to 12 Months of Real-World Treatment With Anifrolumab: Interim Results From the ASTER Study

HTML

Anifrolumab treatment in patients with Sjögren's disease: Efficacy and safety assessment in a randomized, double-blind, placebo-controlled phase-IIa proof-of-mechanism trial (ANISE-II)

PDF

DORIS remission and LLDAS attainment in patients with systemic lupus erythematosus treated with subcutaneous anifrolumab with and without on-study immunosuppressant use: post hoc analysis of the TULIP-SC trial

HTML

The Impact of Subcutaneous Anifrolumab on Patient-Reported Outcomes in Patients With SLE: Results From the Phase 3 TULIP-SC Trial

HTML

Interferon Receptor Blockade With Anifrolumab Mitigates Plasma-Induced Glomerular Inflammation in a 3D Human Glomerular Spheroid Model

HTML

Anifrolumab in patients with systemic lupus erythematosus: real-world data from the Spanish BIOBADASER 3.0 registry

HTML

Real-World Trends in Renal, Hematologic, and Immunologic Parameters With Anifrolumab in Patients Diagnosed With Systemic Lupus Erythematosus Using Administrative Claims Linked to Laboratory Data

HTML

Remission achievement in SLE: real-world evidence from the AZAHAR study in spain

HTML

Single-cell analysis of interferon blockade uncovers B cell repertoire remodeling in systemic lupus erythematosus

HTML

A new endpoint for SLE clinical trials: the Treatment Response Measure for Systemic Lupus Erythematosus clinical trials (TRM-SLE)

PDF

Variation in demographics and clinical features among adults with moderate-to-severe systemic lupus erythematosus by US insurance type

HTML

Association of the treatment response measure for SLE (TRM-SLE) renal response thresholds with long-term outcomes in patients with lupus nephritis

HTML

First phases of the clinical validation of an online-tool estimating one year risk of activity event in Systemic Lupus Erythematosus: the AGILES solution

HTML

Longitudinal serum proteomic signatures associated with durable remission versus relapse after CAR-T therapy in autoimmune diseases

HTML

Phenotypic changes of the peripheral B cell compartment precede the first case of relapsed SLE after CD19 CAR-T cell therapy

PDF

Association between daily dose of oral glucocorticoids and infections in patients with eosinophilic granulomatosis with polyangiitis treated with anti-interleukin-5/receptor therapies

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States